Dr. Veda Giri on Diversity in Clinical Trials
July 12, 2023ID10130
To CiteDCA Citation Guide
- 00:00It is so important to address
- 00:03disparities when it comes to cancer care,
- 00:06and this actually is incredibly
- 00:08important when we think about
- 00:10patients with early onset cancers.
- 00:12We know that minority underserved
- 00:14populations really struggle with
- 00:16many aspects of cancer care,
- 00:18whether it's access to care,
- 00:20whether it is the psychosocial needs,
- 00:22whether it is their socioeconomic needs,
- 00:24and really just in terms of relatability
- 00:27about what they're experiencing from
- 00:29their own cancer diagnosis and their.
- 00:31Cancer journey and we really want
- 00:33this to be across the spectrum from
- 00:36the beginning of a cancer diagnosis
- 00:38all the way into survivorship
- 00:40across the board for patients.
- 00:41So we really want to ensure that we're
- 00:44addressing the needs of patients that
- 00:46are coming from diverse communities,
- 00:48from underserved populations
- 00:49and from minority populations.
- 00:50So the PROSPER study has really been
- 00:53designed to address the needs of minority
- 00:55and underserved populations first.
- 00:57So we are looking at patients that
- 00:59have an early onset cancer diagnosis,
- 01:01whether it's breast cancer or.
- 01:03Colorectal cancer,
- 01:04pancreatic cancer or prostate cancer
- 01:06and who are from black or African
- 01:08ancestry and also Hispanic Latin X
- 01:10or Spanish speaking individuals.
- 01:12And we're very excited to partner
- 01:14with our groups in the community
- 01:16to help really understand the needs
- 01:19of these individuals to be able to
- 01:21really bring forth programs and
- 01:23tools that are really meaningful,
- 01:25impactful and can really make
- 01:27a difference in terms of their
- 01:29cancer treatment and their journey
- 01:31into survivorship.